Banned medicine (Credit-Canva)
The Union Health Ministry implemented a ban on 156 "irrational" FDC medicines, effective immediately. These medicines, including widely used antibiotics, painkillers, and multivitamins, were commonly used to treat fever, cough, and infections. The ban was imposed due to the associated health risks and lack of therapeutic justification for the ingredients in these FDCs.
FDCs or fixed-dosed combinations, also known as "cocktail drugs," are medications that combine multiple drugs in a single pill. They are designed to treat multiple symptoms or conditions simultaneously. While they offer convenience, they can pose significant risks. These risks include the possibility of overdose, adverse interactions between the drugs, and the development of antibiotic resistance. Additionally, many FDC medicines lack sufficient scientific evidence to support their safety and efficacy.
Experts have raised concerns about the use of FDC medicines. They believe that many of these combinations lack sufficient scientific evidence to support their safety and effectiveness. Additionally, the combination of multiple drugs in a single pill can increase the risk of adverse side effects and interactions with other medications.
Experts have also found that FDC medicines may not be as effective as individual drugs in treating certain conditions. It is important to note that safer and more effective alternatives are available for most of the medical conditions that FDC medicines were used to treat. One particular concern is the inclusion of antibiotics in some FDCs. Overuse of antibiotics can contribute to the development of antibiotic resistance, a major public health threat.
The use of FDC medicines can lead to adverse effects, including serious ones. Additionally, safer alternatives, tested in clinical trials, are available to treat the same medical conditions. Experts recommend prescribing drugs individually based on a patient's clinical symptoms rather than combining them in FDCs.
The ban on irrational FDC medicines by the Union Health Ministry can be seen as a positive step towards promoting rational drug use and protecting public health. The goal is to eliminate unnecessary and potentially harmful drug combinations. This is a step forward in reducing the risks associated with medication and ensure safer and more effective treatment options for patients.
Credit: @EmbaCubaUS/X
Scientists in Cuba have developed a novel vaccine against lung cancer that has shown the potential to improve survival rates among people living with the disease.
The vaccine, chemically known as racotumomab, has been developed in collaboration with scientists from Argentina. Vaxira has been approved in Cuba and Argentina for advanced non-small cell lung cancer (NSCLC).
It helps the immune system recognize and destroy lung cancer cells.
According to the Cuban Embassy in the US, the vaccine "works by mimicking a molecule found on cancer cells but almost entirely absent in healthy human tissue". It also targets tumors with remarkable precision and has very few side effects.
While advanced NSCLC has limited curative options and poor survival rates, clinical trials of Vaxira showed a significant improvement in survival.
Notably, "one-year survival among patients receiving the vaccine nearly doubled compared with the control group," the post said.
"Real-world data shows median survival of up to 24.5 months in maintenance therapy," it added.
Improved Survival And Minimal Side Effects
Importantly, the vaccine has demonstrated minimal side effects and is considered suitable for long-term use.
The embassy described the vaccine as affordable and accessible compared with many immunotherapies.
In 2025, Vaxira also received Cuba's National Technological Innovation Award.
The commercial rollout of Vaxira is being facilitated by the international public-private consortium ReComBio, linking Havana's Center of Molecular Immunology (CIM) with Argentina's Elea Laboratories.
Lung Cancer is one of the most common and serious types of cancer. It is also the leading cause of cancer-related deaths worldwide, with approximately 2.5 million new cases and 1.8 million deaths reported in 2022.
According to the American Cancer Society, lung cancer mainly occurs in older people. Most people diagnosed with lung cancer are 65 or older; a very small number of people diagnosed are younger than 45.
The average age of people when diagnosed is about 70.
It is also the leading cause of cancer death in the US, accounting for about 1 in 5 of all cancer deaths.
The two main types of lung cancers are:
Non-small-cell lung cancer (NSCLC): This is the most common form, making up about 80–85% of all cases. NSCLC includes three subtypes:
Small-cell lung cancer (SCLC): Less common than NSCLC, this type tends to grow and spread more quickly.
Lung cancer symptoms can mimic less serious conditions, which is why they’re often dismissed or misdiagnosed. If you experience the following symptoms persistently, don’t ignore them—regardless of your age or smoking history:
Credit: AI generated image
The International Space Station is conducting a very important study as Expedition 74 astronauts are researching how to manufacture large quantities of stem cells for treatment purposes on Earth. Research previously mostly worked on hardware to produce a large amount of stem cells, but now the InSPA-StemCellEX-H2 is trying to produce the cells for medical purposes.
This endeavor will rely on the process called “expansion”, which will use the stem cells from the human body and divide them. Though this is already possible on earth, the quality of created stem cells is far poorer than those from the human body, as it cannot create new cells in the blood, but the ones created in space will solve this problem, which will be crucial in the treatment of leukemia, as they need stem cells in the blood system post-chemotherapy.
Dr. Tobias Niederwieser, assistant research professor at BioServe Space Technologies within the University of Colorado Boulder, says, “The microgravity environment in space is much more suitable for keeping the stem cells in their high-quality state during expansion.” He added, “The result is really to benefit patients in hospitals here on Earth.”
Read Also: Pancreatic Cancer: What Is The Role Of Keratin 17 In Driving The Feared Disease?
Credit: AP
The White House has announced that US President Donald Trump is in “excellent health”. But doctors flag missing medical details.
Trump, 79, underwent an annual medical examination at the Walter Reed National Military Medical Center on May 26. Shortly after the test that lasted three hours, he shared that “everything checked out perfectly.”
Dr. Sean Barbabella, physician to the president, in a memorandum released late last week, said that “President Trump is demonstrating strong cardiac, pulmonary, neurological, and overall physical function.” He added that Trump is “fully fit to carry out all duties of the Commander-in-Chief and Head of State.”
However, doctors stated that the test results authorized by the President for public release contain notable gaps.
According to experts, the physical examination lacks detailed results from tests used to assess cardiovascular health.
Barbabella’s description of Trump’s cardiac health cites results from a coronary CT angiography, an echocardiogram, and an artificial-intelligence-enhanced electrocardiogram analysis.
Jonathan Reiner, Professor of Medicine and Surgery, Interventional Cardiologist, in a post on social media platform X, questioned the need for another coronary artery CT on Trump, as he was last scanned in October.
"We don’t typically scan patients 6 months later unless we are concerned about a finding on the initial scan. What prompted the repeat CT?" he said.
Further, to fully assess the president’s cardiac health, other doctors said they would want to see a calcium score, a description of any plaque in the arteries, and a CAD-RADS score to assess narrowing in the arteries, The Wall Street Journal reported.
“If I were creating a report to send to another physician, I would have mentioned a little bit more about the carotid ultrasound,” William Shutze, a Texas vascular surgeon, was quoted as saying. “What amount of plaque there is going to be—because almost all of us are going to have some buildup there.”
Also Read: President Donald Trump Remains In Excellent Health, Says White House
Further, Trump’s cholesterol numbers and medication regimen also attracted attention from physicians who reviewed the memorandum.
According to the report, his HDL (good cholesterol) level was 70 mg/dL, while his LDL (bad cholesterol) level was 53 mg/dL.
The report said Trump takes rosuvastatin and ezetimibe for cholesterol management.
“He’s got like the best cholesterol numbers you’ll see,” said Daniel Torrent, adding that it is unusual for medication alone to achieve such favorable values. “We don’t usually manage people to the point where they’re that good.”
“That report is almost too good to be true for somebody of his age,” Shutze said. “This seems to be a filtered narrative.”
Notably, neurological condition of Trump, the oldest elected as President of America, has remained a subject of serious discussion, with many doctors pointing out that he's suffering from dementia. But the test results revealed him to be in “normal mental status".
Cognitive function, assessed using the Montreal Cognitive Assessment (MoCA), was also within normal limits, with a score of 30 out of 30.
"Why was the president again given a MOCA dementia screening test? He’s had 3 in the recent past," Reiner asked, while also questioning Trump's "more frequent than the traditional yearly exam?"
Also read: ‘Sea Or See?’ Donald Trump's Remark Sparks Fresh Cognitive Health Speculation
“President Trump has publicly released more detailed information about his health than any other president in history—showing he is in excellent health,” White House communications director Steven Cheung said in a written statement.
He criticized outside physicians for speculating about a report for a patient not under their care, the WSJ said.
The White House added that “the absence of discussion regarding a specific medication, dosage, or historical medical condition should not be interpreted as a lack of monitoring or treatment”.
© 2024 Bennett, Coleman & Company Limited